These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26307969)

  • 1. Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration.
    Parmeggiani F; Costagliola C; Semeraro F; Romano MR; Rinaldi M; Gallenga CE; Serino ML; Incorvaia C; D'Angelo S; De Nadai K; Dell'Omo R; Russo A; Gemmati D; Perri P
    Int J Mol Sci; 2015 Aug; 16(8):19796-811. PubMed ID: 26307969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; D'Angelo S; Perri P; Sebastiani A; Incorvaia C
    Ophthalmology; 2010 Mar; 117(3):517-23. PubMed ID: 20044141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.
    Parmeggiani F; Costagliola C; Gemmati D; D'Angelo S; Perri P; Scapoli GL; Catozzi L; Federici F; Sebastiani A; Incorvaia C
    Pharmacogenet Genomics; 2007 Dec; 17(12):1039-46. PubMed ID: 18004208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic aspects in therapeutic management of subfoveal choroidal neovascularisation: role of factor XIII-A 185 T-allele.
    Parmeggiani F; Costagliola C; Incorvaia C; Sebastiani A; Gemmati D
    Curr Drug Targets; 2011 Feb; 12(2):138-48. PubMed ID: 20887247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration.
    Parmeggiani F; Costagliola C; Gemmati D; D'Angelo S; Perri P; Campa C; Catozzi L; Federici F; Sebastiani A; Incorvaia C
    Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3100-6. PubMed ID: 18378576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic predictors of response to photodynamictherapy.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; Perri P; D'Angelo S; Romano MR; De Nadai K; Sebastiani A; Incorvaia C
    Mol Diagn Ther; 2011 Aug; 15(4):195-210. PubMed ID: 21913742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.
    Sharp DM; Lai S; Markey CM
    Clin Exp Ophthalmol; 2007; 35(1):24-31. PubMed ID: 17300567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Voelker M; Gelisken F; Ziemssen F; Wachtlin J; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1241-6. PubMed ID: 16010552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration.
    Nowak MS; Jurowski P; Grzybowski A; Goś R; Pastuszka M; Kapica A; Śmigielski J
    Med Sci Monit; 2012 Jun; 18(6):CR374-80. PubMed ID: 22648253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
    Essex RW; Qureshi SH; Cain MS; Harper CA; Guymer RH
    Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia.
    Parodi MB; Da Pozzo S; Ravalico G
    Br J Ophthalmol; 2003 Feb; 87(2):177-83. PubMed ID: 12543747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
    Parmeggiani F; Gemmati D; Costagliola C; Sebastiani A; Incorvaia C
    Recent Pat DNA Gene Seq; 2009; 3(2):114-22. PubMed ID: 19519581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.